TickerFacts.

Aspire Biopharma Holdings, Inc. (ASBP): R&D Expense

Annual figures by period end, from SEC filings.

$923.9K
Year ended 2025-12-31
$838.1K
Trailing 12 months to 2026-06-30
2024-12-31: $144.4K2025-12-31: $923.9K$923.9K
2024-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$923.9K+540.0%2026-04-08, From 2025-01-01
2024-12-31$144.4Kn/a2026-04-08, From 2024-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Aspire Biopharma Holdings, Inc. (ASBP)2025-12-31$923.9K+540.0%
Alaunos Therapeutics, Inc. (TCRT)2025-12-31$1.36M+276.5%
Genelux Corp (GNLX)2025-12-31$19.85M+4.5%
Aditxt, Inc. (ADTX)2025-12-31$3.19M-70.7%
PRF Technologies Ltd. (PRFX)2025-12-31$1.14M-90.3%
Jupiter Neurosciences, Inc. (JUNS)2025-12-31$2.09M+323.5%
Talphera, Inc. (TLPH)2025-12-31$6.03M-10.2%
Impact Biomedical Inc. (IBO)2025-12-31$340.0K+22.3%
Lyell Immunopharma, Inc. (LYEL)2025-12-31$158.68M-7.5%

Compare ASBP, TCRT, GNLX, ADTX side by side · Screen every company in Pharmaceutical Preparations ↗